Per-And Polyfluoroalkyl Substances (PFAS)-Free Medical Device Materials Market Global Report 2026

The per-and polyfluoroalkyl substances (PFAS)-free medical device materials market size has grown rapidly in recent years. It will grow from $0.94 billion in 2025 to $1.11 billion in 2026 at a compound annual growth rate (CAGR) of 18.0%. The growth in the historic period can be attributed to increasing regulatory scrutiny of PFAS use, rising awareness of PFAS-related health concerns, growing demand for safer medical device materials, increasing need for chemical-resistant medical components, rising adoption of environmentally preferable healthcare materials.

The per-and polyfluoroalkyl substances (PFAS)-free medical device materials market size is expected to see rapid growth in the next few years. It will grow to $2.16 billion in 2030 at a compound annual growth rate (CAGR) of 18.2%. The growth in the forecast period can be attributed to growing demand for PFAS-free medical polymers and coatings, increasing adoption of sustainable medical device materials, rising demand for non-stick alternatives in surgical applications, expanding use of PFAS-free materials in fluid handling systems, and growing preference for environmentally sustainable healthcare products. Major trends in the forecast period include increasing adoption of PFAS-free medical device materials, rising demand for non-toxic medical material alternatives, growing use of PFAS-free polymers in surgical instruments, increasing demand for chemical-resistant medical materials, and rising adoption of PFAS-free coatings for fluid handling systems.

The increasing regulatory scrutiny of PFAS across medical-device supply chains is expected to propel the growth of the per-and polyfluoroalkyl substances (PFAS)-free medical device materials market in the coming years. Regulatory scrutiny of PFAS refers to increased government oversight of the production, use, import, disclosure, and disposal of materials containing per- and polyfluoroalkyl substances. This scrutiny is intensifying due to concerns regarding environmental persistence, potential health impacts, and PFAS emissions throughout product life cycles. PFAS-free medical device materials enable manufacturers to substitute fluorinated substances in tubing, seals, membranes, coatings, and device housings while reducing regulatory and supply-related risks. For instance, in August 2025, according to the European Chemicals Agency, a Finland-based government agency, the updated PFAS restriction proposal covered 22 sector categories, including medical devices and other medical applications, compared with 14 categories under evaluation in 2024, representing an increase of approximately 57%. Therefore, the increasing regulatory scrutiny of PFAS across medical-device supply chains is driving the growth of the per-and polyfluoroalkyl substances (PFAS)-free medical device materials market.

Major companies operating in the per-and polyfluoroalkyl substances (PFAS)-free medical device materials market are focusing on developing advanced solutions, such as internally lubricated PFAS-free engineering compounds, to reduce friction, enhance wear resistance, and ensure reliable performance in moving medical-device components. Internally lubricated PFAS-free compounds use non-fluorinated functional additives incorporated directly into the polymer matrix to deliver long-lasting lubrication without polytetrafluoroethylene or other PFAS components. For instance, in January 2025, Americhem, a US-based polymer materials manufacturer, launched EcoLube MD, a line of PFAS-free internally lubricated compounds developed for medical devices and healthcare applications. The compounds help reduce friction, component wear, and operating noise in minimally invasive surgical devices, syringe pumps, prosthetics, and surgical robots while supporting plastic-to-plastic and plastic-to-metal applications. Additionally, EcoLube MD underwent ISO 10993-5 biocompatibility testing, supporting medical-device manufacturers in improving regulatory readiness, material safety, and long-term component performance.

In January 2025, GEON Performance Solutions, a US-based provider of performance polymer formulations, vinyl and polyolefin technologies, engineered compounds, and contract manufacturing services, acquired Foster Corporation for an undisclosed amount. Through this acquisition, GEON aimed to strengthen its presence in medical materials, expand its PFAS-free and specialty biomedical polymer capabilities, and broaden its production and distribution reach. Foster Corporation is a US-based provider of custom medical compounds, implantable materials, engineered polymers, thermoplastic polyurethane elastomers, and PFAS-free low-friction additive technologies for medical devices.

Major companies operating in the per-and polyfluoroalkyl substances (PFAS)-free medical device materials market are Compagnie de Saint-Gobain S.A., SABIC, Celanese Corporation, Kuraray Co. Ltd., Evonik Industries AG, Syensqo SA, Avient Corporation, Victrex plc, Trinseo PLC, Nordson Corporation, Freudenberg Medical LLC, Zeus Company Inc., Teknor Apex Company, Ensinger GmbH, RAUMEDIC AG, Optinova AB, One Medical Extrusion, BioInteractions Ltd., Harland Medical Systems Inc., Medical Surface Inc., Surface Solutions Group LLC, LipoCoat B.V., DynaFlex Technologies Inc.

North America was the dominating region in the per-and polyfluoroalkyl substances (PFAS)-free medical device materials market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the per-and polyfluoroalkyl substances (PFAS)-free medical device materials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the per-and polyfluoroalkyl substances (PFAS)-free medical device materials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.